Table 2. Cumulative Incidence of Study End Points by Aspirin Formulation Type and Randomly Assigned Dose of Aspirin.
| End point | Enteric-coated aspirin | Uncoated aspirin | P value for interaction | ||||
|---|---|---|---|---|---|---|---|
| Cumulative incidence (%)a | Adjusted HR (95% CI)b | Cumulative incidence (%)a | Adjusted HR (95% CI)b | ||||
| 81 mg | 325 mg | 81 mg | 325 mg | ||||
| Death, MI, or stroke | 297 (6.6) | 246 (7.1) | 1.13 (0.88-1.45) | 114 (8.5) | 152 (7.6) | 0.99 (0.83-1.18) | .41 |
| All-cause mortality | 155 (3.6) | 146 (3.8) | 0.88 (0.63-1.23) | 56 (3.9) | 99 (4.5) | 0.90 (0.72-1.13) | .90 |
| Major bleeding | 22 (0.5) | 23 (0.7) | 2.37 (1.02-5.50) | 15 (1.0) | 9 (0.4) | 0.89 (0.49-1.64) | .07 |
| GI tract bleeding | 48 (1.2) | 40 (1.2) | 1.27 (0.73-2.22) | 27 (1.7) | 27 (1.4) | 1.19 (0.76-1.84) | .85 |
Abbreviations: GI, gastrointestinal; MI, myocardial infarction.
a
Cumulative incidence is reported at median follow-up, 26.2 months from randomization.
b
Adjustment variables include age, sex, ethnicity, strata, race, prior aspirin use, P2Y12 inhibitor use at baseline, smoking status, no internet use, history of atrial fibrillation, history of bleeding, coronary artery disease, congestive heart failure, cardiovascular disease, diabetes, hypertension, hyperlipidemia, prior MI, and peripheral arterial disease.